Barclays PLC Makes New Investment in Alumis Inc. (NASDAQ:ALMS)

Barclays PLC bought a new position in shares of Alumis Inc. (NASDAQ:ALMS) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,360 shares of the company’s stock, valued at approximately $197,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALMS. Millennium Management LLC acquired a new position in Alumis during the second quarter worth about $3,376,000. Maven Securities LTD acquired a new position in shares of Alumis in the second quarter valued at approximately $332,000. Towerview LLC raised its position in shares of Alumis by 22.6% in the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after buying an additional 70,000 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of Alumis in the third quarter valued at approximately $1,160,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Alumis in the third quarter valued at approximately $27,000.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ALMS shares. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Alumis in a research report on Monday, January 6th. Baird R W raised shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Finally, Robert W. Baird started coverage on shares of Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target for the company. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $26.83.

Alumis Stock Down 3.3 %

Shares of ALMS stock opened at $7.41 on Wednesday. Alumis Inc. has a one year low of $6.75 and a one year high of $13.53. The stock’s 50 day moving average is $8.59.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.